Renaissance Technologies LLC Has $1.36 Million Holdings in OptimizeRx Corp. $OPRX

Renaissance Technologies LLC increased its holdings in OptimizeRx Corp. (NASDAQ:OPRX) by 633.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 216,856 shares of the company’s stock after purchasing an additional 187,278 shares during the period. Renaissance Technologies LLC’s holdings in OptimizeRx were worth $1,362,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of OPRX. Quantbot Technologies LP acquired a new stake in shares of OptimizeRx in the second quarter worth about $44,000. BNP Paribas Financial Markets increased its holdings in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after acquiring an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of OptimizeRx during the 4th quarter valued at about $62,000. Aaron Wealth Advisors LLC bought a new position in shares of OptimizeRx in the 1st quarter valued at approximately $66,000. Finally, Hsbc Holdings PLC bought a new position in shares of OptimizeRx in the 1st quarter valued at approximately $85,000. 76.47% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about OptimizeRx

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q2 earnings and revenue topped estimates. OptimizeRx reported adjusted earnings of $0.16 per share, versus the $0.11 consensus estimate, while revenue of $20.5 million exceeded expectations of $20.2 million. OptimizeRx Corp. Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Full-year guidance was maintained. Management reaffirmed 2026 revenue guidance of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million. The revenue range is broadly consistent with the $97.5 million analyst consensus, reducing the risk of an additional near-term guidance cut. OptimizeRx Reiterates 2026 Revenue Outlook
• Positive Sentiment: Liquidity and debt terms improved. OptimizeRx completed a refinancing featuring a $35 million traditional banking facility, including a $25 million term loan and a $10 million undrawn revolver. The company has repaid $8.3 million of principal since inception, supporting financial flexibility for operations and growth. OptimizeRx Reports Second Quarter 2026 Results
• Neutral Sentiment: Finance leadership appointments were announced. The appointments are intended to support OptimizeRx’s next phase of growth, but investors may focus on execution during the transition. OptimizeRx Announces Finance Leadership Appointments
• Negative Sentiment: Revenue headwinds remain. Although revenue beat estimates, quarterly EPS declined from $0.24 a year earlier, and management continues to navigate revenue pressure. The CFO transition and reaffirmed—rather than raised—outlook may limit further upside until growth reaccelerates. OptimizeRx Q2 2026 Earnings Call Highlights

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of OptimizeRx in a research report on Tuesday. Stephens dropped their price target on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 13th. Wall Street Zen cut shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. UBS Group set a $10.00 price objective on shares of OptimizeRx in a report on Wednesday, May 13th. Finally, Lake Street Capital lowered their target price on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.14.

OptimizeRx Price Performance

NASDAQ OPRX opened at $8.78 on Friday. OptimizeRx Corp. has a twelve month low of $4.54 and a twelve month high of $22.25. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.37 and a current ratio of 5.37. The stock has a market capitalization of $164.71 million, a PE ratio of 38.18 and a beta of 1.08. The stock has a 50-day simple moving average of $6.04 and a 200 day simple moving average of $6.72.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. The firm had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. OptimizeRx had a return on equity of 9.52% and a net margin of 4.66%. Research analysts anticipate that OptimizeRx Corp. will post 0.51 EPS for the current year.

OptimizeRx Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.